DISCLOSURES

What’s New in Ototoxicity Management?
Katharine A. Fernandez
National Institute on Deafness and Other Communication Disorders, NIH
Bethesda, MD

Angela Garinis
Veterans Health Administration (VA) Rehabilitation Research and Development (RR&D), National Center for Rehabilitative Auditory Research, VA Portland Health Care System Department of Otolaryngology/Head and Neck Surgery, Oregon Health & Science University
Portland, OR

Kristin Knight
Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children’s Hospital, Oregon Health & Science University
Portland, OR

Dawn Konrad-Martin
Veterans Health Administration (VA) Rehabilitation Research and Development (RR&D), National Center for Rehabilitative Auditory Research, VA Portland Health Care System Department of Otolaryngology/Head and Neck Surgery, Oregon Health & Science University
Portland, OR

Thais Morata
National Institute for Occupational Safety and Health, NIOSH
Cincinnati, OH

Gayla L. Poling
Department of Otolaryngology—Head and Neck Surgery, Mayo Clinic
Rochester, MN

Kelly M. Reavis
Veterans Health Administration (VA) Rehabilitation Research and Development (RR&D), National Center for Rehabilitative Auditory Research, VA Portland Health Care System OHSU-PSU School of Public Health, Oregon Health & Science University
Portland, OR

Victoria A. Sanchez
Department of Otolaryngology—Head & Neck Surgery, University of South Florida
Tampa, FL

Laura Dreisbach
School of Speech, Language, and Hearing Sciences, San Diego State University
San Diego, CA
Disclosures:
Financial: Angela Garinis currently consults for Horizon Therapeutics. Dawn Konrad-Martin is the co-inventor on two patents involving an ototoxicity monitoring method and portable test system. Gayla L. Poling is a contributing author of the American Academy of Audiology (2009) Position Statement on Ototoxicity and received an honorarium from American Speech-Language-Hearing Association (ASHA) to her institution for ASHA 2021 Continuing Education Online Course on ototoxicity management. Kelly M. Reavis is the co-inventor on a patent involving an ototoxicity monitoring method. Victoria A. Sanchez has sponsored clinical research contracts (to institution) to support research activity from Otonomy Inc., Frequency Therapeutics, Pipeline Therapeutics, Aerin Medical, Oticon Medical, Helen of Troy Ltd., consulting fees from Autifony Therapeutics, Boehringer Ingelheim. Katharine A. Fernandez, Kristin Knight, Thais Morata, and Laura Dreisbach have reported no financial relationships to the content of this article.
Nonfinancial: Katharine A. Fernandez, Angela Garinis, Kristin Knight, Dawn Konrad-Martin, Thais Morata, Gayla L. Poling, Kelly M. Reavis, Victoria A. Sanchez, and Laura Dreisbach are members of the IOMG. This article is intended to align with the IOMG mission and views regarding effective ototoxicity management.